Diagnostic role of Gallium-68 DOTATOC and Gallium-68 DOTATATE PET in patients with neuroendocrine tumors: A meta-analysis

Acta Radiologica

Volumn 55, Issue 4, 2014, Pages 389-398

  Yang, Jigang ^a   Kan, Ying ^a   Ge, Benjamin H ^b   Yuan, Leilei ^a   Li, Chunlin ^a   Zhao, Wenrui ^c  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^c NAVY GENERAL HOSPITAL   (China)

Author keywords

68Ga DOTATATE; 68Ga DOTATOC; Neuroendocrine tumors; PET

Indexed keywords

DIAGNOSIS; MOLECULAR IMAGING; POLYETHYLENE TEREPHTHALATES; POSITRON EMISSION TOMOGRAPHY; TUMORS;

68GA-DOTATATE; 68GA-DOTATOC; AREA UNDER THE ROC CURVE; NEUROENDOCRINE TUMORS; POSITRON EMISSION TOMOGRAPHY (PET); RECEIVER OPERATING CHARACTERISTICS; SENSITIVITY AND SPECIFICITY; SOMATOSTATIN RECEPTORS;

GALLIUM;

DOTATATE GA 68; DOTATOC GA 68; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; 68GA DOTANOC; 68GA DOTATATE; 68GA-DOTANOC; 68GA-DOTATATE; DIAGNOSTIC AGENT; ORGANOMETALLIC COMPOUND;

ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; HUMAN; META ANALYSIS; MOLECULAR IMAGING; NEUROENDOCRINE TUMOR; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUALITY CONTROL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; TUMOR DIAGNOSIS; 68GA-DOTATOC; PET; SCINTISCANNING;

68GA-DOTATATE; 68GA-DOTATOC; NEUROENDOCRINE TUMORS; PET;

HUMANS; NEUROENDOCRINE TUMORS; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY;

EID: 84899860940     PISSN: 02841851     EISSN: 16000455     Source Type: Journal    
DOI: 10.1177/0284185113496679     Document Type: Article

References (42)

1. Heller MT, Shah AB. Imaging of neuroendocrine tumors. Radiol Clin North Am 2011;49:529-548.
2. Chiti A, Fanti S, Savelli G, et al. Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours. Eur J Nucl Med 1998;25:1396-1403.
3. Hoyer D, Bell GI, Berelowitz M, et al. Classification and nomenclature of somatostatin receptors. Trends Pharmacol Sci 1995;16:86-88.
4. Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 2003;30:781-793.
5. Krenning EP, Kwekkeboom DJ, Bakker WH, et al. Somatostatin receptor scintigraphy with [111In-DTPAD- Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20:716-731.
6. Buchmann I, Henze M, Engelbrecht S, et al. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2007;34:1617-1626.
7. Teunissen JJ, Kwekkeboom DJ, Valkema R, et al. Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours. Endocr Relat Cancer 2011;18 (Suppl. 1): S27-S51.
8. Antunes P, Ginj M, Zhang H, et al. Are radiogalliumlabelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging 2007;34:982-993.
9. Poeppel TD, Binse I, Petersenn S, et al. 68Ga- DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors. J Nucl Med 2011;52:1864-1870.
10. Wild D, Schmitt JS, Ginj M, et al. DOTA-NOC, a highaffinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging 2003;30:1338-1347.
11. Ambrosini V, Campana D, Bodei L, et al. 68Ga- DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors. J Nucl Med 2010;51:669-673.
12. Yang J, Hao R, Zhu X. Diagnostic role of 18F-dihydroxyphenylalanine positron emission tomography in patients with congenital hyperinsulinism: a meta-analysis. Nucl Med Commun 2013;34:347-353.
13. Hao R, Yuan L, Kan Y, et al. Diagnostic performance of 18F-FDG PET/CT in patients with fever of unknown origin: a meta-analysis. Nucl Med Commun 2013;34:682-688.
14. Van den Bruel A, Thompson MJ, Haj-Hassan T, et al. Diagnostic value of laboratory tests in identifying serious infections in febrile children: systematic review. BMJ 2011;342:d3082.
15. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-560.
16. Zamora J, Abraira V, Muriel A, et al. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol 2006;6:31.
17. Gabriel M, Decristoforo C, Kendler D, et al. 68Ga- DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007;48:508-518.
18. Putzer D, Gabriel M, Henninger B, et al. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTATyr3- octreotide PET in comparison to CT and bone scintigraphy. J Nucl Med 2009;50:1214-1221.
19. Versari A, Camellini L, Carlinfante G, et al. Ga-68 DOTATOC PET, endoscopic ultrasonography, and multidetector CT in the diagnosis of duodenopancreatic neuroendocrine tumors: a single-centre retrospective study. Clin Nucl Med 2010;35:321-328.
20. Ruf J, Heuck F, Schiefer J, et al. Impact of multiphase 68Ga-DOTATOC-PET/CT on therapy management in patients with neuroendocrine tumors. Neuroendocrinology 2010;91:101-109.
21. Putzer D, Gabriel M, Kendler D, et al. Comparison of (68)Ga-DOTA-Tyr(3)- octreotide and (18)F-fluoro- L-dihydroxyphenylalanine positron emission tomography in neuroendocrine tumor patients. Q J Nucl Med Mol Imaging 2010;54:68-75.
22. Ruf J, Schiefer J, Furth C, et al. 68Ga-DOTATOC PET/CT of neuroendocrine tumors: spotlight on the CT phases of a triple-phase protocol. J Nucl Med 2011;52:697-704.
23. Kayani I, Bomanji JB, Groves A, et al. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG. Cancer 2008;112:2447-2455.
24. Kayani I, Conry BG, Groves AM, et al. A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors. J Nucl Med 2009;50:1927-1932.
25. Haug A, Auernhammer CJ, Wangler B, et al. Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2009;36:765-770.
26. Srirajaskanthan R, Kayani I, Quigley AM, et al. The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy. J Nucl Med 2010;51:875-882.
27. Virgolini I, Ambrosini V, Bomanji JB, et al. Procedure guidelines for PET/CT tumour imaging with 68Ga- DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga- DOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging 2010;37:2004-2010.
28. Reubi JC, Landolt AM. High density of somatostatin receptors in pituitary tumors from acromegalic patients. J Clin Endocrinol Metab 1984;59:1148-1151.
29. Reubi JC, Waser B, Schaer JC, et al. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtypeselective ligands. Eur J Nucl Med 2001;28:836-846.
30. Krenning EP, Bakker WH, Breeman WA, et al. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet 1989; 1:242-244.
31. Hofland LJ, Lamberts SW, van Hagen PM, et al. Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111In-DTPA-D-Phe1]octreotide in somatostatin receptor-positive organs. J Nucl Med 2003; 44:1315-1321.
32. Zhen L, Li H, Liu X, et al. The application of SPECT/CT for preoperative planning in patients with secondary hyperparathyroidism. Nucl Med Commun 2013; 34:439-444.
33. Breeman WA, de Blois E, Sze Chan H, et al. 68)Galabeled DOTA-peptides and (68)Ga-labeled radiopharmaceuticals for positron emission tomography: current status of research, clinical applications, and future perspectives. Semin Nucl Med 2011;41:314-321.
34. Bray M, Di Mascio M, de Kok-Mercado F, et al. Radiolabeled antiviral drugs and antibodies as virusspecific imaging probes. Antiviral Res 2010;88:129-142.
35. Histed SN, Lindenberg ML, Mena E, et al. Review of functional/anatomical imaging in oncology. Nucl Med Commun 2012;33:349-361.
36. Reubi JC, Schar JC, Waser B, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000;27: 273-282.
37. Wild D, Bomanji JB, Benkert P, et al. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors. J Nucl Med 2013;54:364-372.
38. Kabasakal L, Demirci E, Ocak M, et al. Comparison of (6)(8)Ga-DOTATATE and (6)(8)Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2012;39:1271-1277.
39. Oberg K. Gallium-68 somatostatin receptor PET/CT: Is it time to replace (111)Indium DTPA octreotide for patients with neuroendocrine tumors? Endocrine 2012;42:3-4.
40. Souvatzoglou M, Ziegler SI, Martinez MJ, et al. Standardised uptake values from PET/CT images: comparison with conventional attenuation-corrected PET. Eur J Nucl Med Mol Imaging 2007;34:405-412.
41. Seemann MD. Detection of metastases from gastrointestinal neuroendocrine tumors: prospective comparison of 18F-TOCA PET, triple-phase CT, and PET/CT. Technol Cancer Res Treat 2007;6:213-220.
42. Nanni C, Zompatori M, Ambrosini V, et al. The additional diagnostic value of contemporary evaluation of FDG PET/CT scan and contrast enhanced CT imaging both acquired by a last generation PET/CT system in oncologic patients. Biomed Pharmacother 2013;67:172-178.